The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | Managing ALK+ NSCLC

Name: Managing ALK+ NSCLC
Uploaded: 2020-01-30T00:00:00Z
Duration: 1 min 41 s
Description: Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, outlines how will frontline ALK+ non-small cell lung cancer (NSCLC) be managed, highlighting the management of brain metastases This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Stephen Liu • 30 Jan 2020

BTOG 2020

Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib

ALTA-1L

Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, outlines how will frontline ALK+ non-small cell lung cancer (NSCLC) be managed, highlighting the management of brain metastases This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.